
Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma
A retrospective analysis comparing standard-of-care idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel; Carvykti) demonstrated improved survival outcomes but increased toxicity with cilta-cel in patients with relapsed/ …